Prelude Therapeutics Collaborates With Merck To Evaluate PRT3789 Combined With KEYTRUDA (Pembrolizumab) In Patients With SMARCA4-Mutated Cancers

Combining a first-in-class, highly selective SMARCA2 degrader with an anti-PD-1 therapy may potentially enhance the anti-tumor activity of either agent because of the complementary nature of the two mechanisms.

Prelude will sponsor the clinical trial and Merck will provide KEYTRUDA.